DFX Intelligence
Unicycive Therapeutics, Inc.
Venture-backed company · Stage unknown· Los Altos, CA
As of · the latest observation of this company; each round carries its own date
Form D industry: Biotechnology
Public company. Publicly listed (UNCY); its private filings are not venture rounds.
As of · the latest observation of this company; each round carries its own date
1 additional officer or director
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 4 directorsboard
4 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Drawing the relationship network…
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 1
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 0
Financing history
1 round
- Mar 13, 2024Form D equity offering · $50.0M (form d sold) · 25 investorsFact Form D · “Unicycive Therapeutics, Inc. filed Form D: $50,000,000 sold of $50,000,000, Biotechnology”
Investors on record
0 edges
No named investor yet.
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.none on record
Outcome stated by investors
No firm portfolio page lists this company, so no outcome is stated.
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.none on record
No lender position matched to this company.
People
2 officers, 4 directors
- John Townsend Chief Financial Officer sec.gov
- Shalabh Gupta Chief Executive Officer, President and Chairman of the Board of Directors sec.gov
- Sandeep Laumas Director Fact
- Gaurav Aggarwal Director Fact
- John Ryan Director Fact
Timeline
2 events
- Sep 28, 2026Form 8-K filed 2026-09-29 reports the appointment of Meredith S. Manning as director of Unicycive Therapeutics, Inc., effective 2026-10-01Director appointed Fact SEC 8-K Item 5.02 officer and director…
- Mar 20, 2024Unicycive Therapeutics, Inc. filed Form D: $50,000,000 sold of $50,000,000, BiotechnologyForm D filed Fact Form D
Evidence
14 observations
Every observation on this company
- Entity type: Corporation Mar 20, 2024 Fact Form D
- Form D industry group: Biotechnology Mar 20, 2024 Fact Form D
- Amendment: false Mar 20, 2024 Fact Form D
- Revenue range (Form D): Decline to Disclose Mar 20, 2024 Fact Form D
- Incorporated: overFiveYears Mar 20, 2024 Fact Form D
- Jurisdiction: Delaware Mar 20, 2024 Fact Form D
- Amount sold (Form D): $50.0M Mar 20, 2024 Fact Form D
- Offering amount (Form D): $50.0M Mar 20, 2024 Fact Form D
- Exemptions: 06b Mar 20, 2024 Fact Form D
- First sale: 2024-03-13 Mar 20, 2024 Fact Form D
- Investors (Form D): 25 Mar 20, 2024 Fact Form D
- Minimum investment (Form D): 0 Mar 20, 2024 Fact Form D
- Securities offered: Equity, option Mar 20, 2024 Fact Form D
- Office address: Mar 20, 2024 Fact Form D
Record history
1 dated event on the change ledger, latest event first
- Form D filed2024-03-20source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.